Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of Single-dose Pegfilgrastim for CD34 + Cell Mobilization in Healthy Volunteers: A Phase 2 Study.
Goto H, Sugita J, Hasegawa Y, Hayasaka K, Sunagoya K, Hatase R, Nishida M, Ichihashi Y, Odera M, Senjo H, Yokoyama S, Ara T, Shiratori S, Endo T, Hino M, Maeda Y, Sawa M, Sato N, Teshima T. Goto H, et al. Among authors: teshima t. Transplantation. 2024 Apr 1;108(4):996-1003. doi: 10.1097/TP.0000000000004880. Epub 2024 Mar 23. Transplantation. 2024. PMID: 38012835 Free PMC article. Clinical Trial.
Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial.
Fukuhara N, Kato K, Goto H, Takeshi T, Kawaguchi M, Tokushige K, Akashi K, Teshima T, Harigae H, Schuster SJ, Thieblemont C, Dreyling M, Fowler N. Fukuhara N, et al. Among authors: teshima t. Int J Hematol. 2023 Feb;117(2):251-259. doi: 10.1007/s12185-022-03481-y. Epub 2022 Nov 21. Int J Hematol. 2023. PMID: 36404384 Free PMC article. Clinical Trial.
Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan.
Goto H, Kitawaki T, Fujii N, Kato K, Onishi Y, Fukuhara N, Yamauchi T, Toratani K, Kobayashi H, Yoshida S, Shimo M, Onodera K, Senjo H, Onozawa M, Hirata K, Yokota I, Teshima T. Goto H, et al. Among authors: teshima t. Int J Clin Oncol. 2023 Jun;28(6):816-826. doi: 10.1007/s10147-023-02334-w. Epub 2023 Apr 18. Int J Clin Oncol. 2023. PMID: 37071252
Acute Onset of Constrictive Pericarditis Due to Acute Myelomonocytic Leukemia: A Case and Literature Review.
Kosaka N, Uchiyama T, Onozawa M, Nagai J, Koya J, Ishizaka S, Nagai T, Ikebe Y, Kato K, Tanei ZI, Sakakibara-Konishi J, Hasegawa Y, Ohigashi H, Goto H, Hashimoto D, Ujiie H, Hirano S, Konno S, Anzai T, Taniguchi K, Tanaka S, Teshima T. Kosaka N, et al. Among authors: teshima t. Intern Med. 2024 Dec 15;63(24):3359-3365. doi: 10.2169/internalmedicine.3505-24. Epub 2024 Apr 16. Intern Med. 2024. PMID: 38631853 Free article. Review.
Event-free survival at 36 months is a suitable endpoint for diffuse large B-cell lymphoma patients treated with immunochemotherapy: real-world evidence from the North Japan Hematology Study Group.
Izumiyama K, Inao T, Goto H, Harada S, Senjo H, Suto K, Hashiguchi J, Ogasawara R, Saga T, Igarashi T, Wakasa K, Kasahara I, Takeda Y, Yamaguchi K, Shigematsu A, Takahata M, Fujimoto K, Haseyama Y, Nagashima T, Sakai H, Kakinoki Y, Kurosawa M, Yokota I, Teshima T. Izumiyama K, et al. Among authors: teshima t. Haematologica. 2024 Nov 1;109(11):3631-3640. doi: 10.3324/haematol.2023.284841. Haematologica. 2024. PMID: 38867578 Free PMC article.
Real-World Outcomes of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation in Japan: Retrospective Analysis of the Transplant Registry Unified Management Program Registry.
Kanda J, Mitsuyoshi T, Sakurai M, Nishimori H, Murata M, Uchida N, Doki N, Inamoto Y, Nishida T, Tanaka M, Katayama Y, Eto T, Matsuoka KI, Yoshihara S, Sawa M, Kawakita T, Jun G, Kurata M, Ichinohe T, Fukuda T, Teshima T, Atsuta Y, Terakura S. Kanda J, et al. Among authors: teshima t. Transplant Cell Ther. 2024 Sep;30(9):907.e1-907.e16. doi: 10.1016/j.jtct.2024.06.023. Epub 2024 Jul 2. Transplant Cell Ther. 2024. PMID: 38960321
Mocravimod, a Selective Sphingosine-1-Phosphate Receptor Modulator, in Allogeneic Hematopoietic Stem Cell Transplantation for Malignancy.
Dertschnig S, Gergely P, Finke J, Schanz U, Holler E, Holtick U, Socié G, Medinger M, Passweg J, Teshima T, Stylianou C, Oehen S, Heim D, Bucher C. Dertschnig S, et al. Among authors: teshima t. Transplant Cell Ther. 2023 Jan;29(1):41.e1-41.e9. doi: 10.1016/j.jtct.2022.10.029. Epub 2022 Nov 4. Transplant Cell Ther. 2023. PMID: 36343893 Free article. Clinical Trial.
1,120 results